# Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial

> **NCT04835506** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 124 (estimated)

## Conditions studied

- Crohn Disease
- Ulcerative Colitis
- Inflammatory Bowel Diseases

## Interventions

- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT04835506
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-01
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04835506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04835506, "Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04835506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*